Plasma homocyst(e)ine concentration, but not MTHFR genotype, is associated with variation in carotid plaque area.

BACKGROUND AND PURPOSE Elevated plasma homocyst(e)ine [H(e)] concentration is associated with premature atherosclerosis. A common cause of elevated plasma H(e) concentration is a thermolabile mutation (677T) in the gene encoding methylenetetrahydrofolate reductase (MTHFR). We sought to determine whether plasma H(e) concentration or MTHFR genotype would be more strongly associated with carotid plaque area (CPA), a potential intermediate phenotype of atherosclerosis. METHODS In 307 subjects who were ascertained through a premature atherosclerosis clinic, we measured CPA with 2-dimensional ultrasound and also determined traditional atherosclerosis risk factors, in addition to plasma H(e) concentration and MTHFR genotypes. RESULTS We found that the frequency of the MTHFR 677T allele was 0.363 in this sample. Mean plasma H(e) concentration was significantly higher in 677T/T homozygotes than in 677T/C heterozygotes and 677C/C homozygotes (17. 1+/-13.7 versus 13.5+/-6.1 versus 12.6+/-5.9 micromol/L, respectively, P<0.001). Analysis of variance showed that CPA was significantly associated with age, sex, smoking, diabetes, hypertension, and hyperlipidemia (each P<0.05). When plasma H(e) concentration was included in the model, it was significantly associated with CPA (P<0.05). However, when the MTHFR genotype was included in the model, it was not associated with CPA (P=0.50). Furthermore, there was a significant correlation of CPA with plasma H(e) (r=0.23, P<0.0001). However, the mean CPA did not differ between subjects according to genotype. CONCLUISONS: Thus, plasma H(e), but not MTHFR genotype, is significantly associated with carotid atherosclerosis, suggesting that the biochemical test may be sufficient to identify patients who may be at increased risk of atherosclerosis through this mechanism.

[1]  J. Toole,et al.  Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study. , 1990, Circulation.

[2]  KojiMaemura,et al.  Genetic Polymorphism of 5,10-Methylenetetrahydrofolate Reductase (MTHFR) as a Risk Factor for Coronary Artery Disease , 1997 .

[3]  F. Bernardi,et al.  Hyperhomocyst(e)inemia and a common methylenetetrahydrofolate reductase mutation (Ala223Val MTHFR) in patients with inherited thrombophilic coagulation defects. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[4]  M. Malinow,et al.  Homocyst(e)inemia in daily practice: levels in coronary artery disease , 1990 .

[5]  J. Spence,et al.  Measurement of atherosclerosis: development of an atherosclerosis severity index. , 1989, Clinical and experimental hypertension. Part A, Theory and practice.

[6]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[7]  N. Samani,et al.  Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction. , 1996, QJM : monthly journal of the Association of Physicians.

[8]  L. Taylor,et al.  Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. , 1989, Circulation.

[9]  D. Cole,et al.  Clinical chemistry and molecular biology of homocysteine metabolism: an update. , 1997, Clinical biochemistry.

[10]  T M Morgan,et al.  Remodeling of coronary arteries in human and nonhuman primates. , 1994, JAMA.

[11]  Reinhardt,et al.  Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and the risk of coronary artery disease , 1998, European journal of clinical investigation.

[12]  J. Toole,et al.  Evaluation of a scoring system for extracranial carotid atherosclerosis extent with B-mode ultrasound. , 1986, Stroke.

[13]  W H Baker,et al.  Quantitative analysis of continuous-wave Doppler spectral broadening for the diagnosis of carotid disease: results of a multicenter study. , 1986, Journal of vascular surgery.

[14]  P. Mannucci,et al.  A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V:Q506). , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[15]  S. Vasikaran,et al.  Methylenetetrahydrofolate reductase gene and coronary artery disease. , 1997, Circulation.

[16]  J. Kastelein,et al.  Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. , 1997, Circulation.

[17]  J. Wainscoat,et al.  Factor V Leiden and Thermolabile Methylenetetrahydrofolate Reductase in Extreme Old Age , 1997, Thrombosis and Haemostasis.

[18]  D. Weiss,et al.  Cardiac Prognosis of Patients With Carotid Stenosis and No History of Coronary Artery Disease , 1994, Stroke.

[19]  Richard A. Kronmal,et al.  Distribution and Correlates of Sonographically Detected Carotid Artery Disease in the Cardiovascular Health Study , 1992, Stroke.

[20]  S. Friedman,et al.  Use of diastolic velocity ratios to predict significant carotid artery stenosis. , 1988, Stroke.

[21]  J. Carlquist,et al.  A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. , 1997, Journal of the American College of Cardiology.

[22]  T. Raghunathan,et al.  Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. , 1997, Circulation.

[23]  Y. Yazaki,et al.  Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. , 1997, Circulation.

[24]  D. Reed,et al.  A prospective study of cerebral artery atherosclerosis. , 1988, Stroke.

[25]  J. Toole,et al.  Individual Variation in Susceptibility to Extracranial Carotid Atherosclerosis , 1988, Arteriosclerosis.

[26]  A. Marian,et al.  A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. , 1997, Atherosclerosis.

[27]  R. Rozen.  Molecular genetic aspects of hyperhomocysteinemia and its relation to folic acid. , 1996, Clinical and investigative medicine. Medecine clinique et experimentale.

[28]  M. Norusis,et al.  Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. , 1991, American journal of human genetics.

[29]  D. Wilcken,et al.  Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[30]  Stephen B. Manuck,et al.  Psychological stress and the progression of carotid artery disease , 1997, Journal of hypertension.

[31]  J. Hardebo,et al.  Moderate Homocysteinemia - A Possible Risk Factor For Arteriosclerotic Cerebrovascular Disease , 1984, Stroke.

[32]  J F Toole,et al.  Risk factors for extracranial carotid artery atherosclerosis. , 1987, Stroke.

[33]  R. Clarke,et al.  Hyperhomocysteinemia: an independent risk factor for vascular disease. , 1991, The New England journal of medicine.

[34]  M. Secic,et al.  Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. , 1994, Clinical chemistry.

[35]  H. Markus,et al.  A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. , 1997, Stroke.

[36]  R. D'Agostino,et al.  Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. , 1995, The New England journal of medicine.

[37]  W. Willett,et al.  Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. , 1996, Circulation.

[38]  N. Schork,et al.  Research utility of noninvasive methods for measurement of cardiac output , 1987, Clinical pharmacology and therapeutics.

[39]  S. Yusuf,et al.  Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials. , 1993, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[40]  G. Boers,et al.  Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. , 1985, The New England journal of medicine.

[41]  L. Taylor,et al.  Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease. , 1996, Circulation.

[42]  L. Chambless,et al.  Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. , 1993, Circulation.

[43]  P. Frosst,et al.  Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[44]  M. Malinow,et al.  Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. , 1998, The New England journal of medicine.

[45]  W. M. van Baal,et al.  A Randomized Controlled Study of the Effects of 17Beta‐Estradiol‐Dydrogesterone on Plasma Homocysteine in Postmenopausal Women , 1998, Obstetrics and gynecology.

[46]  F. Costa,et al.  The Mutation Ala677→Val in the Methylene Tetrahydrofolate Reductase Gene: A Risk Factor for Arterial Disease and Venous Thrombosis , 1997, Thrombosis and Haemostasis.

[47]  C. Zarins,et al.  Compensatory enlargement of human atherosclerotic coronary arteries. , 1987, The New England journal of medicine.